Lexology December 6, 2025
On 6 December 2025, Biocon Limited announced that Biocon Biologics will be integrated into it, becoming a wholly owned subsidiary of the company upon completion of the transaction, expected to occur by 31 March 2026.
Under the proposed transaction, Biocon Limited will acquire the minority stakes in Biocon Biologics currently held by Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP, through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, reportedly valuing Biocon Biologics at USD 5.5 billion. Biocon will also acquire the residual stake held by Mylan Inc (Viatris) for USD 815...
Today's Sponsors
Today's Sponsor